NewsAn Overview of MASH: Advancements in Diagnosis, Treatment, and the Role of Real-World DataRead more →Read more →
NewsNew Patient-Reported Outcome Insights from Target RWE: NASH-CHECK Reveals Stability Over Time and Worse Scores Among Those with Decompensated Cirrhosis of Patients with MASLDRead more →Read more →
An Overview of MASH: Advancements in Diagnosis, Treatment, and the Role of Real-World DataRead more →
New Patient-Reported Outcome Insights from Target RWE: NASH-CHECK Reveals Stability Over Time and Worse Scores Among Those with Decompensated Cirrhosis of Patients with MASLDRead more →
ACG 2024: Target RWE Presents Key MASH and EGIDs Data from Leading Liver Disease & Gastroenterology Real-World RegistriesRead more →
Real World TARGET-NASH Analysis Shows High Concordance Between New MASLD Definitions and Prior TARGET-NASH Pragmatic DefinitionsRead more →
GLP-1 Use and NASH-CHECK Patient-Reported Outcomes Studies from Target RWE Presented at EASL 2024Read more →
TARGET-NASH Offers Unprecedented Glimpse into Growing Public Health Concerns with Few Treatment OptionsRead more →
World-Leading Real World Data Registry, TARGET-NASH, Surpasses 7,000+ Enrolled Patients and 500,000+ Months of Patient Follow-UpRead more →
Event Recap Blog: TARGET-NASH Analysis Presented at ISPOR 2023 and Target RWE Leaders Present at PMSA 2023Read more →
Validation of a Pragmatic Clinical Risk-Based Classification of NASH - New Supporting Real World Evidence from TARGET-NASHRead more →
Nonalcoholic Fatty Liver Disease (NAFLD) Research from Target RWE's Real-World Study Presented at International Liver Congress 2022Read more →
Large Real-World Study Uncovers Higher Prevalence of Non-Alcoholic Fatty Liver Disease Markers, Liver Biopsy, and Cirrhosis in ChildrenRead more →
Peer-Reviewed Target RWE Study Finds Wide Variance in Nonalcoholic Steatohepatitis (NASH) Pathology ReportingRead more →
Update from Paris NASH 2021: New Target RWE Nonalcoholic Steatohepatitis (NASH) Data Presented at This Year's MeetingRead more →
TARGET-NASH Study Finds Statins Underutilized in Patients with NAFLD and At-Risk of Heart DiseaseRead more →
TARGET-NASH Real-World Study Reveals Two Thirds Of Patients With NAFLD Had No Record Of Liver BiopsyRead more →
Target RWE Data Presented at AASLD Virtual Meeting Provides Important Updates for NASH and PBC CommunitiesRead more →
TARGET-NASH Data Publication Finds Nearly One In Five Patients With NAFLD Have Prior Prescription Opioid UseRead more →
Asian Lean Patients With NAFLD Are 53% Less Likely To Have Cirrhosis, Cardiovascular, And Metabolic Diseases - Latest Data Findings Released From TARGET-NASH StudyRead more →
TARGET PharmaSolutions to Advance Research in NASH and Hepatitis B Through New Collaboration with Gilead SciencesRead more →
Intercept (ICPT) Extends Strategic Partnership with TARGET PharmaSolutions for TARGET-NASHRead more →
Bristol-Myers Squibb (BMY) Extends Strategic Partnership with TARGET PharmaSolutions for TARGET-NASHRead more →
